Spinal Cord Injury
Regenerative medicine research for spinal cord injury is active worldwide, and Japan has a distinct regulatory framework for regenerative medicine. This overview explains the condition, the current state of research, how to read study records and regulatory files, and how to examine a public claim using original sources.
Japan Medical — Independent Health Information. Japan Medical is an independent health-information publication. It summarizes publicly available research and regulatory records and does not provide individual assessments, provider matching, referrals, appointment booking or service coordination.
What Current Evidence Does and Does Not Establish
This summary condenses the evidence into four points. Most human research in this area is early-phase: it can show whether a procedure can be delivered safely and studied further, but it cannot by itself show improved movement, sensation or daily function.
Some small studies and case reports describe partial changes in some participants after cell procedures. Small samples, short follow-up and missing control groups mean such reports cannot be read as demonstrated treatment effects. The sections after this summary show how to weigh any individual claim.
A large global burden
About 15.4 million people worldwide were living with spinal cord injury in 2021, according to WHO estimates.[1]
Registered research exists
ClinicalTrials.gov lists registered studies involving stem cells and spinal cord injury (search term: stem cell spinal cord injury; checked July 28, 2026; records change over time). Registry inclusion shows that a study record exists. It does not by itself establish study completion, regulatory approval, safety or effectiveness.[2]
No established cure
No cell-based therapy is established as standard care for spinal cord injury, and regulators warn about unapproved products marketed with unsupported claims.[3]
Japan’s distinct framework
Japan manages cell procedures through a filed provision-plan system. A filed plan permits a procedure under stated conditions; it is not a government judgment that the procedure works.[4]
Spinal Cord Injury in Numbers
These global figures describe the burden of the condition itself. They say nothing about how well any experimental procedure works.
Global figures: WHO spinal cord injury fact sheet, estimates for 2021.[1] Most spinal cord injuries result from preventable trauma such as falls and road traffic injuries, and in-hospital mortality is nearly three times higher in low- and middle-income countries than in high-income countries.[1] Males are affected more often than females, and mortality risk is highest in the first year after injury.[1]
What Spinal Cord Injury Involves
Spinal cord injury means damage to the bundle of nerves that carries signals between the brain and the body. Causes include trauma such as falls, road traffic injuries and violence, and non-traumatic causes such as tumors, degeneration, vascular problems and infections.[1]
What a person experiences depends on where the injury sits and how severe it is. Injuries higher in the spine affect more of the body, and cervical injuries can affect breathing. These differences matter when reading any research claim, because studies rarely include the same mix of injuries.[1]
Complete and incomplete injury
A complete injury means total loss of motor and sensory function below the injury level. An incomplete injury means some signal still crosses the injury, so some movement or feeling remains.
Paraplegia and tetraplegia
In paraplegia, arm function is preserved while the trunk and legs are affected. In tetraplegia, the arms are affected as well. The injury level shapes daily life and rehabilitation goals.
Secondary conditions
Spinal cord injury can affect bladder and bowel control, blood pressure, body temperature and sexual function, and it raises the risk of serious secondary conditions.[1]
Why repair is difficult
Central nervous system neurons regrow poorly. After injury, inflammation damages surviving tissue, and a glial scar forms a barrier around the lesion.
How clinicians grade severity
Clinicians commonly grade spinal cord injury with the International Standards for Neurological Classification of Spinal Cord Injury, whose impairment scale runs from grade A to grade E.[5] The AIS is assigned through a standardized neurological examination. The simplified descriptions below are for terminology only and cannot be used for self-classification.
Research Approaches at a Glance
Cell-based and cell-free approaches under study for spinal cord injury remain research-stage.[2] Each card below states what the approach is and the one distinction that matters most when reading a claim about it.
Autologous bone-marrow cells
Cells from a person’s own bone marrow. Studies differ in cell preparation, dose and administration route, so one study’s result cannot be generalized to every bone-marrow cell procedure.
Research stageAdipose-derived cells
Mesenchymal stromal cells from fat tissue. The broad label adipose-derived does not identify a specific product, preparation or manufacturing method.
Research stageDonor-derived cells
Cells from donated tissue such as umbilical cord. Tissue source, donor material, manufacturing process and product batch must be distinguished before comparing claims.
Research stageNeural stem cells
Cells intended to become nervous-system tissue. Reading a claim requires attention to cell survival, integration, long-term follow-up and product-specific evidence.
Research stageiPS cell-derived products
Reprogrammed cells guided toward neural cell types. iPS technology is a platform, not a specific product approval or a conclusion about human benefit.
Research stageExosomes and cell-free products
Fluids collected from cell cultures, without living cells. Actual composition, production method, dose and human study records need to be confirmed for any specific product.
Research stageHow might cells act on an injured spinal cord? Laboratory or animal research suggests transplanted cells may release supportive signalling molecules, may modulate inflammation, may encourage small-vessel growth and may alter the scar environment. These mechanisms have been proposed from preclinical work and have not established clinical benefit in people.
How to Read a ClinicalTrials.gov Record
A registered study record has a defined structure. The fields below decide what a record can actually tell a reader.[6][7][8]
Status and sponsor
Study Status shows whether a study is recruiting, active or completed. Sponsor names who runs it.
Type and phase
Study Type separates interventional from observational work. Phase indicates the question being asked.
Enrollment and allocation
Enrollment is the planned or actual participant count. Allocation shows how participants were assigned to groups.
Masking and model
Masking shows who knew which assignment each participant received. Intervention Model describes the group structure.
Outcomes
The Primary Outcome is the main measured question. Secondary Outcomes are additional measures.
Dates
Study Start, Primary Completion Date and Study Completion Date mark different milestones.
Results and harms
Results Posted shows whether outcome data and Adverse Events have been published in the record.
Record history
Record History shows how the entry changed over time, including outcomes added or revised.
A recruiting or active status describes the study record under its stated conditions. It does not show that the intervention has produced a benefit. Study registration, study completion and posted study results are three different states.[6] Results posted in a registry and results published in a journal are also separate things, and one does not guarantee the other.[7]
The Evidence Strength Ladder
Different study types answer different questions. This ladder is not a simple good-or-bad score: each rung has a legitimate use and a defined limit.[9][10]
Laboratory research
Shows how cells behave in controlled conditions. It cannot show effects in people.
Animal research
Tests ideas in living organisms. Findings often fail to translate to humans.
Case report
Describes one person in detail. It cannot separate a treatment effect from coincidence.
Case series
Describes several similar people. Without a comparison group, causes stay uncertain.
Single-arm study
Follows one treated group over time. It measures change, not what caused the change.
Controlled study
Compares treated and untreated groups. It begins to separate effect from background change.
Randomized study
Assigns participants by chance, reducing selection differences between groups.
Systematic review
Combines many studies with defined methods. Its strength depends on the studies inside it.
Regulatory review
Assesses a specific product file for a defined use. Its conclusion covers that file only.
An observed change and a demonstrated treatment effect are not the same conclusion. Only controlled comparisons can begin to establish causation, and no rung extends findings to other products or other patient populations on its own.[10] A claim that cites only the lower rungs should be read as early-stage, whatever words are used to describe it.
What Outcomes Are Actually Measured
Spinal cord injury studies measure specific, named outcomes. Knowing what each measure captures prevents a vague improvement claim from sounding more precise than it is.[5][7]
AIS grade: the overall impairment category from the standardized neurological examination
Motor score: strength measured across defined muscle groups
Sensory score: light-touch and pin-prick responses at defined skin points
Independence in daily activities: eating, dressing, transfers and similar tasks
Respiratory function: breathing capacity, critical in cervical injuries
Bladder and bowel outcomes: control and management of these functions
Pain and spasticity: symptom scores that strongly affect daily life
Quality of life: structured questionnaires on overall well-being
Serious adverse events: significant harms recorded during the study
Follow-up duration: how long participants were observed after the procedure
The primary outcome is the one question the study was built around; secondary outcomes add context. The AIS is assigned through a standardized neurological examination and cannot be determined through a webpage. A statistically detectable change is not automatically the same as a meaningful improvement in everyday independence.[7] When a report mentions improvement without naming the measure, the first question is which of these outcomes actually changed.
How Japan Regulates Cell Procedures
Japan’s framework for regenerative medicine includes risk classification, committee review and public records. These distinctions matter when reading any claim connected to Japan.
A dedicated safety law
A national law on the safety of regenerative medicine has been in force since 2014, setting safety-management rules for cell procedures provided as medical care.[4]
Risk classification
Procedures are managed in risk classes, with stricter review requirements for higher-risk classes.[4]
Public records exist
Filed provision plans are published in an official database, so a plan’s existence and basic details can be checked by anyone.[11]
Filing is not proof
A filing, registration or plan submission does not show that a procedure works, and approval of one product does not extend to any other product, procedure or institution.[4][12]
One conditional approval
In December 2018, PMDA records show a conditional, time-limited approval for one specific autologous bone-marrow cell product for spinal cord injury, with further data collection required.[12]
A claim about Japan can usually be checked: identify the plan number or product name cited, then compare it with the matching public record.[11]
Six Regulatory Terms That Should Not Be Mixed Together
Claims about Japan often blend different regulatory states into one impressive-sounding word. Each term below means something specific, lives in a specific record, and confirms only what that record contains.[4][13]
Clinical-trial registration
A study’s entry in a public registry. It confirms a study plan exists. It cannot confirm completion, results or benefit.[6]
Ethics or committee review
A certified committee’s examination of a plan’s safety arrangements. It confirms review took place. It cannot confirm that a procedure works.[4]
Filed provision plan
The safety-management filing recorded in the published plans database. It confirms a procedure may be offered under stated conditions, nothing more.[11]
Cell-processing facility registration
The notification status of the facility that prepares cells. It confirms the facility is on record. It cannot confirm the quality of any single batch.[4]
Product marketing approval
A PMDA review decision for a specific manufactured product and defined use. It confirms that file only.[12]
Conditional, time-limited approval
An approval granted on probable benefit with mandatory further data collection. It is temporary and product-specific, not a final verdict.[13]
A status attached to one product, plan or study does not extend to another product, procedure, institution or use.[12]
What a Public Record Can and Cannot Tell You
Official databases are powerful for checking facts and useless for checking promises. The two lists below separate the two jobs.[11][12]
A public record may help confirm
- Institution name and location
- Plan title and plan number
- Risk class and reviewing committee
- Product name and applicant
- Approval date and approval type
- Study status and sponsor
A public record cannot by itself confirm
- Individual suitability or actual benefit
- Long-term outcome or provider quality
- An advertised success rate
- Complete costs or patient satisfaction
- Causation behind any improvement
- Endorsement by Japan Medical
The existence of a record and the strength of evidence are separate questions. A record tells you something exists; only the underlying evidence can say what it means.[6] When a record and a marketing claim disagree, the record is the more reliable starting point.[18]
Why an Improvement Does Not Automatically Prove an Effect
People can improve after any procedure for reasons unrelated to the procedure itself. These are the limitations that decide how much weight an improvement report can carry.[10][14]
No control group
Nothing to compare the change against.
Small sample
A few participants cannot represent everyone.
Mixed injuries
Different injury levels and severities recover differently on their own.
Concurrent rehabilitation
Intensive therapy given at the same time can drive change.
Measurement variability
Scores fluctuate between examiners and sessions.
Short or lost follow-up
Early changes may fade; missing participants hide outcomes.
Selective reporting
Reporting only favorable outcomes among many measured.
Case stories
Individual accounts cannot show what caused a change.
Statistical importance and practical importance also differ. Without an appropriate comparison, the cause of an observed change may remain uncertain.[10]
Product Identity Matters
Stem cells or exosomes is not a sufficient product description. Regulators note that products sold under these broad labels vary widely, and a claim is only checkable when the product behind it is specified.[3][15]
Autologous (own tissue) or donor-derived
Tissue source: bone marrow, fat, umbilical cord or other
Living cells or cell-free material
Processing and manufacturing method
Administration route
Dose and number of administrations
Manufacturing site
Sterility testing and release criteria
Product-specific human evidence
The exact record (plan, approval or study) the claim points to
Two procedures described with the same broad label may differ in cell source, processing, dose, administration route and supporting evidence. These fields help determine whether two claims are even referring to the same type of product.[15]
Rehabilitation, Assistive Technology and Long-Term Function
Long-term outcome after spinal cord injury depends less on any single procedure than on a chain of established measures, beginning with timely acute care and continuing for years. WHO describes these measures as essential for survival, functioning and the prevention of premature mortality.[1][16]
Ongoing medical management
- Acute care, then multidisciplinary rehabilitation to rebuild function and independence
- Pressure-injury prevention and respiratory complication management
- Bladder and bowel management, pain and spasticity care
- Ongoing follow-up to detect and manage secondary conditions
Participation and support
- Assistive products that restore everyday activity and independence
- Mental health support for the person and caregivers
- Education, employment and community participation
- Caregiver support and self-management skills
How to Check a Public Claim
The following fields may appear in official records or provider documents. Their presence does not establish effectiveness, endorsement or suitability for any individual.
Before relying on a claim, readers may request the following information and compare it with the relevant official records.[10][18] A provider unable or unwilling to identify these fields leaves the claim unverifiable.
Institution name, location, plan title and reviewing committee, compared with the relevant official public record
Provision-plan number, procedure name and risk class
Name of the certified committee that reviewed the plan
Cell-processing facility name and its registration status
Cell source and the release criteria used for sterility and viability
A procedure-specific consent form listing known and potential risks
Total costs, possible additional costs, and cancellation or refund terms
Follow-up schedule and the adverse-event reporting process
Whether the procedure is research or non-research medical care
Whether results have been published in a peer-reviewed journal
Documented Risks and Uncertainties
Regulators list the following risk categories for unproven regenerative therapies, and a licensed provider must explain procedure-specific risks through consent documentation.[3]
Infection and contamination
Any collection, processing or infusion step can introduce infectious agents if controls fail.
Immune and inflammatory reactions
The body can react to transplanted cells, especially donor-derived material.
Unintended tissue growth
Cells that grow in unintended ways, including tumour formation, are a recognised concern.
Collection-site complications
Harvesting bone marrow or fat is itself a medical procedure with its own risks.
Procedure-level risks
Injection into or near the spinal canal carries risks specific to that anatomy.
No measurable benefit
A procedure may provide no measurable benefit, while medical, practical and financial risks may still remain.
Note: this list reflects the position of the United States regulator. It describes general risk categories and does not determine the legal status of any procedure in Japan.[3]
Frequently Asked Questions
What does current evidence establish?
What does a registered study record mean?
What does conditional and time-limited approval mean?
What does a filed provision plan mean?
What can a public record confirm?
What can Japan Medical answer?
About Japan Medical
Publication details
Publisher. Japan Medical.
Author. Japan Medical.
Prepared by. Japan Medical.
Source review. Japan Medical.
Purpose. Japan Medical summarizes publicly available research, regulatory documents and registry records for general information.
Review boundary. Japan Medical checks whether page statements match the cited original sources. No individual medical-review credential is claimed.
Commercial disclosure. Japan Medical does not accept provider-placement fees or referral compensation on this page.
Last reviewed. July 28, 2026.
Corrections. Readers may contact Japan Medical to report a source, date, link or transcription error.
Sources Used on This Page
Numbered in order of first appearance. Dynamic records are marked with the date they were checked.
- WHO — Spinal Cord Injury Fact Sheethttps://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury
- ClinicalTrials.gov — Stem Cell and Spinal Cord Injury Searchhttps://clinicaltrials.gov/search?term=stem cell spinal cord injury
- FDA — Important Patient and Consumer Information About Regenerative Medicine Therapieshttps://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
- MHLW — Regenerative Medicine Provision Planshttps://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/plan.html
- American Spinal Injury Association — ISNCSCI Worksheethttps://asia-spinalinjury.org/international-standards-neurological-classification-sci-isncsci-worksheet/
- ClinicalTrials.gov — How to Read a Study Recordhttps://clinicaltrials.gov/study-basics/how-to-read-study-record
- ClinicalTrials.gov — How to Read Study Resultshttps://clinicaltrials.gov/study-basics/how-to-read-study-results
- ClinicalTrials.gov — Glossaryhttps://clinicaltrials.gov/study-basics/glossary
- NIH — Clinical Research Trials and You: The Basicshttps://www.nih.gov/health-information/nih-clinical-research-trials-you/basics
- U.S. Federal Trade Commission — Health Products Compliance Guidancehttps://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
- MHLW — Published Provision Plans Databasehttps://saiseiiryo.mhlw.go.jp/published_plan/index/
- PMDA — Review Reports: Regenerative Medical Productshttps://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
- PMDA — Reviews and Related Serviceshttps://www.pmda.go.jp/english/review-services/reviews/0003.html
- NINDS — Spinal Cord Injuryhttps://www.ninds.nih.gov/health-information/disorders/spinal-cord-injury
- FDA — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomeshttps://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
- WHO — Rehabilitation Fact Sheethttps://www.who.int/news-room/fact-sheets/detail/rehabilitation
- WHO — Assistive Technology Fact Sheethttps://www.who.int/news-room/fact-sheets/detail/assistive-technology
- MedlinePlus — Evaluating Health Informationhttps://medlineplus.gov/evaluatinghealthinformation.html
- Google Search Central — Helpful, Reliable, People-First Contenthttps://developers.google.com/search/docs/fundamentals/creating-helpful-content
Ask Japan Medical
Send a source link, study identifier, public claim or regulatory term. Japan Medical answers questions about published information and public records only.
Japan Medical answers questions about published sources, study records, regulatory terms and public claims. Please do not send medical records, imaging, test results or identity documents.